SOHO 2022 | The promise of combining venetoclax with gilteritinib for the treatment of FLT3-mutated AML
In this video, Amir T. Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, comments on the promise of combining venetoclax with gilteritinib for the treatment of patients with relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML), and highlights some recent data from a study evaluating this combination. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Clinical trial support – Abbvie, Servier, BMS
Consulting – Abbvie, Servier, BMS, Genentech, PureTech, Ipsen, Forma, Kite, Celgene, Amgen, Novartis, Takeda, Astellas, Immunogen, Mablytics, EnClear, Orum
